Enarodustat (BioDeep_00000838397)
代谢物信息卡片
Enarodustat
化学式: C17H16N4O4 (340.1171496)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
InChI: InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24)
描述信息
C78275 - Agent Affecting Blood or Body Fluid
Enarodustat is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM. Enarodustat has the potential for renal anemia treatment.
同义名列表
3 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- KEGGdrug: D11523
- PubChem: 50899324
- DrugBank: DB14985
- ChEMBL: CHEMBL4297619
- CAS: 1494680-11-3
- CAS: 1262132-81-9
- medchemexpress: HY-109057
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ryo Fujikawa, Yuji Nagao, Masaki Fujioka, Tadao Akizawa. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2022 Aug; 26(4):679-693. doi:
10.1111/1744-9987.13820. [PMID: 35218616] - Tadao Akizawa, Masaomi Nangaku, Takuhiro Yamaguchi, Ryosuke Koretomo, Kazuo Maeda, Osamu Yamada, Hideki Hirakata. Two long-term phase 3 studies of enarodustat (JTZ-951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND-Long and HD-Long studies.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
2022 Apr; 26(2):345-356. doi:
10.1111/1744-9987.13724. [PMID: 34390314] - Sudhakar M Pai, Hiroyuki Yamada, Robert B Kleiman, Rui Zhuo, Qingtao Mike Huang, Ryosuke Koretomo. Thorough QT/QTc Evaluation of the Cardiac Safety of Enarodustat (JTZ-951), an Oral Erythropoiesis-Stimulating Agent, in Healthy Adults.
Clinical pharmacology in drug development.
2021 08; 10(8):884-898. doi:
10.1002/cpdd.933. [PMID: 34159762] - K Fukui, T Tanaka, M Nangaku. Enarodustat to treat anemia in chronic kidney disease.
Drugs of today (Barcelona, Spain : 1998).
2021 Aug; 57(8):491-497. doi:
10.1358/dot.2021.57.8.3304877. [PMID: 34405206] - Sudhakar Pai, Mike Qingtao Huang, Koichi Maki, Michael Waldron, Tomonori Yoshikawa, Tara Keller, James Burnett. A highly sensitive and selective UPLC-MS/MS assay for the determination of enarodustat (JTZ-951) in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2021 Jun; 1176(?):122754. doi:
10.1016/j.jchromb.2021.122754. [PMID: 34052557] - Yuichi Shinozaki, Kenji Fukui, Hatsue Kobayashi, Hiromi Yoshiuchi, Akira Matsuo, Mutsuyoshi Matsushita. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
European journal of pharmacology.
2021 May; 898(?):173990. doi:
10.1016/j.ejphar.2021.173990. [PMID: 33657422] - Sudhakar M Pai, Hiroyuki Yamada. Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease.
Clinical pharmacology in drug development.
2021 05; 10(5):463-470. doi:
10.1002/cpdd.923. [PMID: 33788422] - Anthony Markham. Enarodustat: First Approval.
Drugs.
2021 Jan; 81(1):169-174. doi:
10.1007/s40265-020-01444-3. [PMID: 33320297] - Sudhakar M Pai, Jeffrey Connaire, Hiroyuki Yamada, Seiji Enya, Barbara Gerhardt, Michihide Maekawa, Hiromasa Tanaka, Ryosuke Koretomo, Tomohiro Ishikawa. A Mass Balance Study of 14 C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on Hemodialysis.
Clinical pharmacology in drug development.
2020 08; 9(6):728-741. doi:
10.1002/cpdd.752. [PMID: 31876104] - Sho Hasegawa, Tetsuhiro Tanaka, Tomoyuki Saito, Kenji Fukui, Takeshi Wakashima, Etsuo A Susaki, Hiroki R Ueda, Masaomi Nangaku. The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
Kidney international.
2020 05; 97(5):934-950. doi:
10.1016/j.kint.2019.12.007. [PMID: 32171449] - Marie Ito, Tetsuhiro Tanaka, Taisuke Ishii, Takeshi Wakashima, Kenji Fukui, Masaomi Nangaku. Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.
Kidney international.
2020 04; 97(4):687-701. doi:
10.1016/j.kint.2019.10.020. [PMID: 32033782] - Mai Sugahara, Shinji Tanaka, Tetsuhiro Tanaka, Hisako Saito, Yu Ishimoto, Takeshi Wakashima, Masatoshi Ueda, Kenji Fukui, Akira Shimizu, Reiko Inagi, Toshimasa Yamauchi, Takashi Kadowaki, Masaomi Nangaku. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
Journal of the American Society of Nephrology : JASN.
2020 03; 31(3):560-577. doi:
10.1681/asn.2019060582. [PMID: 31996409] - Lisa Uchida, Tetsuhiro Tanaka, Hisako Saito, Mai Sugahara, Takeshi Wakashima, Kenji Fukui, Masaomi Nangaku. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
American journal of physiology. Renal physiology.
2020 02; 318(2):F388-F401. doi:
10.1152/ajprenal.00419.2019. [PMID: 31841388] - Takeshi Wakashima, Tetsuhiro Tanaka, Kenji Fukui, Yasumasa Komoda, Yuichi Shinozaki, Hatsue Kobayashi, Akira Matsuo, Masaomi Nangaku. JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors.
American journal of physiology. Renal physiology.
2020 01; 318(1):F14-F24. doi:
10.1152/ajprenal.00323.2019. [PMID: 31630548] - Kenji Fukui, Yuichi Shinozaki, Hatsue Kobayashi, Katsuya Deai, Hiromi Yoshiuchi, Takuya Matsui, Akira Matsuo, Mutsuyoshi Matsushita, Tetsuhiro Tanaka, Masaomi Nangaku. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
European journal of pharmacology.
2019 Sep; 859(?):172532. doi:
10.1016/j.ejphar.2019.172532. [PMID: 31301309] - Hisako Saito, Tetsuhiro Tanaka, Mai Sugahara, Shinji Tanaka, Kenji Fukui, Takeshi Wakashima, Masaomi Nangaku. Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet.
Laboratory investigation; a journal of technical methods and pathology.
2019 07; 99(8):1217-1232. doi:
10.1038/s41374-019-0239-4. [PMID: 30952940] - Tadao Akizawa, Masaomi Nangaku, Takuhiro Yamaguchi, Masanobu Arai, Ryosuke Koretomo, Atsushi Matsui, Hideki Hirakata. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
American journal of nephrology.
2019; 49(2):165-174. doi:
10.1159/000496929. [PMID: 30699415] - Tadao Akizawa, Masaomi Nangaku, Takuhiro Yamaguchi, Masanobu Arai, Ryosuke Koretomo, Kazuo Maeda, Yuya Miyazawa, Hideki Hirakata. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
Nephron.
2019; 143(2):77-85. doi:
10.1159/000500487. [PMID: 31117088] - NULL. Erratum Regarding 'Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD' (Am J Kidney Dis. 2017;69[6]:815-826).
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2017 06; 69(6):869. doi:
10.1053/j.ajkd.2017.04.001. [PMID: 28532635]